Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Phase Response Clear all
Completed Phase 1 Interventional

Clofarabine in Chronic Lymphocytic Leukemia

NCT00028418
View directory record Official record
Conditions
Hematologic Neoplasms, Lymphoproliferative Disorders, Leukemia, Leukemia, Lymphocytic, Chronic
Interventions
Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 18, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
PF-00489791, placebo, sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 18, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 18, 2026, 4:06 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

NCT03485963
View directory record Official record
Conditions
HIV Infections
Interventions
HST-NEETs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

NCT01794702
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine, Idarubicin, Cytarabine, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 18, 2026, 4:06 AM EDT
Recruiting No phase listed Observational

Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock

NCT07825363
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
Interventions
NIRSense Tissue Oximetry Sensor System
Device
Lead sponsor
NIRSense Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 18, 2026, 4:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Confusion in the Elderly After Colon Surgery

NCT01623297
View directory record Official record
Conditions
Confusion, Inflammation, Acute Phase Reaction, Surgery, Delirium
Interventions
Not listed
Lead sponsor
New York Hospital Queens
Other
Eligibility
65 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

NCT00580125
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-00217830, Placebo, Aripiprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

NCT04470050
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Isoflavones and Acute-phase Response in Chronic Renal Failure

NCT00029796
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
soy isoflavones
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 18, 2026, 4:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

NCT00866281
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
midostaurin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

NCT01786343
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 18, 2026, 4:06 AM EDT
Withdrawn Phase 2 Interventional

Sulindac for Patients With AML

NCT01843179
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Sulindac
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 4 Interventional

Perioperative Steroid Dosing on the APR in AIS

NCT05561725
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Dexamethasone postoperative, Standard of Care
Drug
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Not listed Not applicable Interventional

Remote Ischemic Conditioning in Abdominal Surgery

NCT03234543
View directory record Official record
Conditions
Laparotomy, Laparoscopy, Retroperitoneal Disease, Pelvis Disease, Pancreatic Diseases, Liver Diseases, Gastrointestinal Disease, Urologic Diseases, Complication of Surgical Procedure
Interventions
Remote ischemic conditioning, No Remote ischemic conditioning
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 18, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

NCT01266083
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
Galinpepimut-S, GM-CSF, Montanide
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 18, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

NCT04195347
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
CM4620
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Charlotte, North Carolina • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 4:06 AM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 18, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

NCT06917911
View directory record Official record
Conditions
Core Binding Factor Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
70
States / cities
Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 4:06 AM EDT